Levamlodipine

Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Hypertension
Adult: As monotherapy or in combination with other antihypertensive agents: Usual initial dose: 2.5 mg once daily. In patients already on other antihypertensive therapy, a lower initial dose of 1.25 mg once daily may be used. Titrate dose every 1-2 weeks according to blood pressure goals and patient response. Max: 5 mg once daily.
Elderly: As monotherapy or in combination with other antihypertensive agents: Initially, 1.25 mg once daily. Titrate dose every 1-2 weeks according to blood pressure goals and patient response.
Child: 6-17 years As monotherapy or in combination with other antihypertensive agents: 1.25-2.5 mg once daily.
Nhóm bệnh nhân đặc biệt
Debilitated patients: Initially, 1.25 mg once daily. Titrate dose every 1-2 weeks according to blood pressure goals and patient response.
Suy gan
Initially, 1.25 mg once daily. Titrate dose slowly in patients with severe impairment.
Cách dùng
May be taken with or without food.
Thận trọng
Patient with severe aortic stenosis, hypertrophic cardiomyopathy and left ventricular outflow tract obstruction. Debilitated patients. Hepatic impairment. Children and elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Symptomatic hypotension; worsening angina and acute MI (particularly in patients with severe obstructive CAD).
Cardiac disorders: Palpitations.
Gastrointestinal disorders: Nausea, abdominal pain.
General disorders and administration site conditions: Fatigue, oedema.
Nervous system disorders: Dizziness, somnolence.
Vascular disorders: Flushing.
Chỉ số theo dõi
Monitor blood pressure and heart rate.
Quá liều
Symptoms: Peripheral vasodilation with marked hypotension and possibly reflex tachycardia. Management: Start active cardiac and respiratory monitoring. Monitor blood pressure frequently. In case of hypotension, provide CV support, including elevation of extremities and administration of fluids. If hypotension remains unresponsive to such measures, consider administration of vasopressors (e.g. phenylephrine) while monitoring circulating volume and urine output.
Tương tác
Increased systemic exposure with moderate and strong CYP3A inhibitors. May increase the serum concentrations of simvastatin, ciclosporin and tacrolimus.
Ảnh hưởng đến kết quả xét nghiệm
May cause a false-negative aldosterone/renin ratio.
Tác dụng
Description:
Mechanism of Action: Levamlodipine is the pharmacologically active isomer of amlodipine, a dihydropyridine Ca channel blocker. Amlodipine inhibits Ca ion transmembrane influx into vascular smooth muscles and, to a lesser extent, cardiac muscle cells. It acts directly on vascular smooth muscle, leading to a decrease in peripheral vascular resistance and a reduction in blood pressure.
Synonym(s): S-amlodipine.
Onset: Gradual.
Duration: ≥24 hours.
Pharmacokinetics:
Absorption: Bioavailability: 64-90%. Time to peak plasma concentration: 6-12 hours.
Distribution: Plasma protein binding: Approx 93%.
Metabolism: Extensively metabolised in the liver (approx 90%) to form inactive metabolites.
Excretion: Via urine (60% as metabolites, 10% as unchanged drug). Terminal elimination half-life: Approx 30-50 hours.
Đặc tính

Chemical Structure Image
Levamlodipine

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 9822750, Levamlodipine. https://pubchem.ncbi.nlm.nih.gov/compound/Levamlodipine. Accessed Nov. 25, 2024.

Bảo quản
Store between 15-30°C.
Phân loại MIMS
Thuốc đối kháng calci
Phân loại ATC
C08CA17 - levamlodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Tài liệu tham khảo
Anon. Levamlodipine Maleate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 05/11/2024.

Brayfield A, Cadart C (eds). Levamlodipine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/11/2024.

Conjupri Tablet (CSPC Ouyi Pharmaceutical Co. Ltd). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 05/11/2024.

Levamlodipine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 05/11/2024.

Levamlodipine. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 05/11/2024.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Levamlodipine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2026 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com